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Abstract
Background: We conducted a nationwide study in Denmark to identify clinical features and prognostic
factors in patients with Streptococcus pneumoniae according to the focus of infection.
Methods: Based on a nationwide registration, clinical information's was prospectively collected from all
reported cases of pneumococcal meningitis during a 2-year period (1999–2000). Clinical and laboratory
findings at admission, clinical course and outcome of the disease including follow-up audiological
examinations were collected retrospectively. The focus of infection was determined according to the
clinical diagnosis made by the physicians and after review of the medical records.
Results: 187 consecutive cases with S. pneumoniae meningitis were included in the study. The most
common focus was ear (30%), followed by lung (18%), sinus (8%), and other (2%). In 42% of cases a primary
infection focus could not be determined. On admission, fever and an altered mental status were the most
frequent findings (in 93% and 94% of cases, respectively), whereas back rigidity, headache and convulsion
were found in 57%, 41% and 11% of cases, respectively. 21% of patients died during hospitalisation (adults:
27% vs. children: 2%, Fisher Exact Test, P < 0.001), and the causes of death were due to neurological – and
systemic complications or the combination of both in 8%, 5% and 6% of cases, respectively. Other causes
(e.g. gastrointestinal bleeding, incurable cancer) accounted for 2% of cases. 41% of survivors had
neurological sequelae (hearing loss: 24%, focal neurological deficits: 16%, and the combination of both: 1%).
The mortality varied with the focus of the infection (otogenic: 7%, sinusitic: 33%, pneumonic: 26%, other
kind of focus: 50%, no primary infection focus: 21%, Log rank test: P = 0.0005). Prognostic factors
associated with fatal outcome in univariate logistic regression analysis were advanced age, presence of an
underlying disease, history of headache, presence of a lung focus, absence of an otogenic focus, having a
CT-scan prior to lumbar puncture, convulsions, requirement of assisted ventilation, and alterations in
various CSF parameters (WBC <500 cells/µL, high protein levels, glucose levels<1 mmol/L, low CSF/blood
glucose levels), P < 0.05. Independent prognostic factor associated with fatal outcome in multivariate
logistic regression analysis was convulsions (OR: 4.53, 95%CI: (1.74–11.8), p = 0.002), whereas presence
of an otogenic focus was independently associated with a better survival (OR: 6.09, 95%CI: (1.75–21.2), P
= 0.005).
Conclusion: These results emphasize the prognostic importance of an early recognition of a predisposing
focus to pneumococcal meningitis.
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Introduction
Although treatment regimens for Streptococcus pneumoniae
meningitis are still improving (e.g. adjunctive therapy
with corticosteroids [1]), the mortality rate has not
changed over half a century and remains as high as ~25%
with neurological sequelae in up to half of survivors [2].
Pneumococcal meningitis is secondary to a primary infec-
tion focus (e.g. ear focus in ~30%, lung focus in ~25%,
sinusitic focus in ~10%), and bacteraemia is present in up
to 3/4 of all cases [3-6]. Consequently, the causes of death
from pneumococcal meningitis may be multifactoral and
due to both neurological complications (e.g. brain herni-
ation, seizures) and systemic complications (e.g. septic
shock, multiorgan dysfunction) [5,7,8]. Therefore, predis-
posing condition such as the focus of the infection may be
of significant importance for the outcome of the disease
[5,6,9]. However, no previous studies have to our knowl-
edge addressed clinical features of pneumococcal menin-
gitis according to the focus of infection.
Several risk factors associated with a poor clinical out-
come of pneumococcal meningitis such as advanced age,
presence of an underlying disease, pneumonia or bacter-
aemia, decreased mental status, delay in initiation of anti-
biotic therapy, and alterations in various CSF parameters
(e.g. low CSF glucose levels, low CSF WBC) have been
identified in previous studies, but have been inconsistent
findings [3-5,9-17]. However, previous studies have been
relatively small in size or did not apply multivariate statis-
tics in their risk factor analysis, and may not be compara-
ble due to differences in study population (e.g. children
vs. adults, patients admitted to intensive care units vs. all
cases), which may well explain conflicting results.
The aim of the present nationwide study of 187 consecu-
tive Danish cases with pneumococcal meningitis over a
two-year period (1999–2000) was to investigate clinical
features according to the focus of infection. Moreover, we
wanted to clarify whether the focus is an independent
prognostic factor for the outcome of pneumococcal men-
ingitis.
Methods
Identification of patients
Pneumococcal meningitis is a notifiable disease in Den-
mark, and all cases are reported to the Department of Epi-
demiology, Statens Serum Institut (SSI). In addition, all
pneumococcal isolates obtained from CSF and blood are
sent to the National Reference Laboratory at the Strepto-
coccus Unit, SSI for serotyping and confirmatory antibi-
otic susceptibility testing. If a case with a positive CSF
isolate were not reported initially, a request was sent out
to ensure the reporting of the case. Therefore, the study
represents a nationwide collection of consecutive cases
with pneumococcal meningitis, and all notified patients
with onset of pneumococcal meningitis during the period
1. January 1999 to 31. December 2000 were included in
the study. Pneumococcal meningitis was defined as a CSF
culture with S. pneumoniae or CSF pleocytosis (≥ 10 leu-
kocytes/mL) in conjunction with a blood culture of S.
pneumoniae [18].
Data collection
Clinical and laboratory information is provided with the
notification form (i.e. diagnosis, time of onset of symp-
toms, clinical features, vaccination status, time of lumbar
puncture and the results of CSF microscopy and CSF/
blood culture), and hospital discharge records have pro-
spectively been collected from all reported cases. Addi-
tional medical records including laboratory findings at
admission, clinical course and outcome of the disease, as
well as results from follow-up audiological examinations
were collected retrospectively. Admission and discharge
records including time of death were retrospectively con-
trolled in the Danish civil registration database and in the
national hospital registration database (Grønne system).
A total of 178 out of 188 isolates (95%) obtained from
CSF and blood of the reported cases were referred to the
National Reference Laboratory at the Streptococcus Unit,
SSI for serotyping and confirmatory antibiotic susceptibil-
ity testing. Serotyping was performed by the Quelling
reaction using type-specific pneumococcal rabbit antisera
(Pneumosera®, SSI). Testing for penicillin susceptibility
was performed with oxacillin (1 µg disk, AB Biodisk
Solna, Sweden) with subsequent determination of MIC
values for all isolates with reduced susceptibility using the
E-test (AB Biodisk). The results of susceptibility testing
performed at the local hospital laboratory were also col-
lected from 7 isolates that were not sent to SSI.
Definition of the focus
The focus of infection was determined according to the
clinical diagnosis made by the physicians, and was con-
firmed respectively by review of the medical records. 1)
The presence of an otogenic focus was determined by oto-
scopic examination, often performed by an otologist, and
did not require the isolation of pneumococci from middle
ear fluid. 2) The presence of a sinusitic focus was deter-
mined after examination by an otologist and confirmed
by cranial radiography of the sinuses including CT-scan/
MR-scan, and did not require the isolation of pneumo-
cocci from sinus fluid. 3) The presence of a pneumonic
focus was determined by clinical examination together
with confirmatory chest radiography, and did not require
isolation of pneumococci from sputum. 4) The presence
of other foci was determined by clinical signs of infection
together with isolation of pneumococci in samples from
these foci. 5) No primary infection focus was considered,
when no primary infection foci could be detected, andB
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Table 1: Characteristics of 187 patients with S. pneumoniae meningitis according to the focus of the infection.
% or median (25/75 percentiles) 
and (No/total)
All cases
(N = 187)
Otogenic focus
(N = 57)
Sinusitic focus
(N = 15)
Pneumonic focus
(N = 33)
Other foci
(N = 4)
No primary infection focus
(N = 78)
Sex (female/male) 91/96 34/23 9/6 15/18 3/1 30/48
Age (in years) 55 (22–69) 56 (37–71) 66 (39–73) 58 (44–70) 75 (55–81) 49 (1–64)
<16 years of age 24% (45/187) 21% (12/57) 7% (1/15) 9% (3/33) 0% (0/4) 37% (29/78)
Predisposing condition* 12 % (23/185) 11% (6/57) 27% (4/15) 6% (2/33) 0% (0/4) 15% (11/76)
Underlying disease§ 18% (33/185) 14% (8/57) 20% (3/15) 36% (12/33) 25% (1/4) 12% (9/76)
Clinical features on admission
Fever 93% (155/166) 98% (55/56) 92% (12/13) 100% (27/27) 75% (3/4) 95% (63/66)
Headache 41% (48/116) 44% (17/39) 63% (5/8) 40% (6/15) 0% (0/3) 39% (20/51)
Back rigidity 57% (86/151) 65% (34/52) 75% (9/12) 41% (9/22) 25% (1/4) 54% (33/61)
Decreased consciousness 94% (165/176) 98% (53/54) 86% (12/14) 93% (28/30) 100% (4/4) 92% (68/74)
Convulsion
(Debut before/
after admission)
31% (54/175)
11% (19/175)
17% (29/175)
23% (13/56)
5% (3/56)
18% (10/56)
33% (5/15)
20% (3/15)
13% (2/15)
41% (12/29)
10% (3/29)
31% (9/29)
50% (2/4)
0% (0/0)
50% (2/4)
31% (22/71)
14% (10/71)
17% (12/71)
Duration of symptoms 2 days (2–4) (111/187) 2 days (1–4) (53/57) 3 days (2–7) (11/15) 3 days (2–8) (12/33) 3 days (1–5) (3/4) 2 days (2–3) (37/76)
Mechanical ventilation 58% (97/168) 49% (25/51) 50% (6/12) 77% (24/31) 100% (4/4) 54% (38/70)
CT-scan before lumbar puncture 11% (21/187) 7% (4/57) 13% (2/15) 12% (4/33) 0% (0/4) 14% (11/78)
Steroid therapy 16% (26/163) 14% (7/51) 8% (2/13) 19% (5/26) 0% (0/4) 17% (12/69)
Paraclinical findings CSF WBC 
(cells/µL)
1842 (291–4419) (149/187) 2844 (914–4553)## (50/57) 119 (41–5489) (12/15) 497 (66–2708) (24/33) 38 (1–235) (4/4) 2475 (850–4650)¤¤ (59/78)
CSF protein (g/L) 2.7 (1.4–5.8) (123/187) 3.1 (1.7–5.9) (44/57) 4.0 (1.0–9.0) (10/15) 2.8 (1.0–6.0) (18/33) 8.2 (0.5–10) (3/4) 2.3 (1.3–4.4) (48/78)
CSF glucose (mmol/L) 0.9 (0.4–2.8) (129/187) 0.9 (0.4–2.6) (45/57) 0.7 (0.1–3.0) (11/15) 0.9 (0.3–3.2) (21/33) 2.4 (0.6–3.7) (3/4) 0.9 (0.4–2.9) (49/78)
CSF/blood glucose ratio 0.1 (0.04–0.4) (93/187) 0.1 (0.05–0.3) (29/57) 0.05 (0.01–0.4) (9/15) 0.07 (0.01–0.4) (18/33) 0.5 (0.09–0.9) (2/4) 0.2 (0.04–0.5) (35/78)
Positive CSF culture 95% (176/186) 93% (53/57) 100% (15/15) 91% (29/32) 100% (4/4) 96% (75/78)
Blood WBC (109 cells/L) 17.3 (10.5–25.7) (134/187) 17.6 (10.5–24.1) (29/57) 20.0 (8.9–26.2) (12/15) 12.6 (7.9–22.9) (23/33) 10.2 (6.7–19) (3/4) 17.9 (14.1–27.7) (50/78)
Positive blood culture 67% (124/186) 74% (42/57) 60% (9/15) 72% (23/32) 100% (4/4) 60% (46/78)
Decreased penicillin 
susceptibility
6% (10/183) 7% (4/57) 7% (1/14) 0% (0/32) 0% (0/4) 7% (5/75)
Death during hospitalisation 21% (39/187) 7% (4/57)** 33% (5/15) 26% (12/33) 50% (2/4) 21% (16/78)
1. Neurological causes# 8% (16/187)$ 3.5% (2/57) 13% (2/15) 12% (4/33) 0% (0/4) 10% (8/78)
2. Systemic causes¤ 5% (9/187)$ 0% (0/57) 13% (2/15) 9% (3/33) 25% (1/4) 4% (3/78)
3. Other causes& 2% (3/187) 0% (0/57) 0% (0/15) 9% (3/33) 0% (0/4) 0% (0/78)
Combination of 1 and 2 6%(11/187)$ 3.5% (2/57) 7% (1/15) 6% (2/33) 25% (1/4) 7% (5/78)
Sequelae 41% (57/138) 54% (26/48) 22% (2/9) 45% (9/20) 100% (1/1) 32% (19/60)
1. Hearing loss 24% (34/138) 33% (16/48) 11% (1/9) 20% (4/20) 0% (0/1) 22% (13/60)
2. Neurologic abnormalityˆ 16% (22/138) 21% (10/48) 11% (1/9) 25% (5/20) 100% (1/1) 8% (5/60)
Combination of 1 and 2 1% (1/138) 0% (0/48) 0% (0/9) 0% (0/20) 0% (0/1) 2% (1/60)
Number of days hospitalised 
among survivors
13 (10–20) 13 (10–19) 11 (10–36) 22 (13–32) 44 13 (11–16)
* Predisposing condition was defined a previous head trauma, liquorrhoea, dura disruption etc.
§Underlying disease was defined as previous splenectomy, presence of immunodeficit, cancer, diabetes mellitus, alcoholism, or the use of immunosuppressive drugs.
# Includes brain herniation, cerebrovascular complications.
¤ Includes septic shock, multiple-organ dysfunction.
& Includes withdrawal of care due to incurable cancer (1 patient), gastrointestinal bleeding (+/- Bilroth II operation, 2 patients).
ˆNeurologic abnormality was defined as presence of aphasia, ataxia and paresis at discharge.
$ 1 patient also had gastrointestinal bleeding/Billroth II operation.
##Significant difference vs. sinusitic cases, pneumonic cases, and cases with other foci (Mann Whitney test with Bonferonis correction P < 0.05).
¤¤ Significant difference vs. sinusitic cases, and cases with other foci (P < 0.05).
**Significant difference vs. pneumonic cases (Fisher Exact test with Bonferonis correction, P = 0.01).BMC Infectious Diseases 2005, 5:93 http://www.biomedcentral.com/1471-2334/5/93
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when pneumococci were not isolated from other body
fluids than CSF and/or blood.
Ethics
All protocols were approved by the local scientific ethic
committee and the Danish Data Protection Agency
(#2002-41-2278).
Statistical analysis
All results are given as medians and interquartile range.
Fisher's exact test was used for analysis of categorical data.
For analysis of continuous data, comparison between two
groups was performed by use of the non-parametric
Mann-Whitney test and between more than two groups by
use of the non-parametric Kruskal-Wallis test. For analysis
between groups according to the focus, a Bonferroni cor-
rection of 10 was used to compensate for multiple com-
parisons. Survival was estimated by the methods of
Kaplan-Meier and compared by the Log rank test. Relative
risk for progression to death was calculated using univari-
ate and multivariate logistic regression analysis. Only var-
iables with more than 80% of values available and with a
P-value <0.2 were tested in the multivariate analysis. P <
0.05 was considered significant.
Table 2: Characteristics of 187 patients with S. pneumoniae meningitis according to age groups
% (No/total) or Median (25/75 percentiles) Adults (≥ 16 years) (N = 142) Children (<16 years) (N = 45)
Sex (female/male) 71/71 20/25
Age 61 years (50–71) 12 month (7–18)
Predisposing condition* 13% (19/140) 9% (4/45)
Underlying disease§ 23% (32/140) 2% (1/45)**
Clinical features on admission
Fever 97% (119/123) 95% (41/43)
Headache 57% (47/82) 3% (1/34)**
Back rigidity 61% (67/110) 46% (19/41)
Decreased consciousness 96% (131/137) 87% (34/39)
Convulsion
(Debut before/
after admission)
28% (37/130)
6% (8/130)
22% (29/130)
37% (17/45)
24% (11/45)**
13% (6/45)
Duration of symptoms 2 days (2–4) (83/142) 2 days (2–6) (28/45)
Mechanical ventilation 67% (86/128) 28% (11/40)**
CT-scan preceding lumbar puncture 13% (19/142) 4% (2/45)
Steroid therapy 7% (8/121) 43% (18/42)**
Paraclinical findings CSF WBC (cells/µL) 2475 (122–4659) (109/142) 1690 (775–2622) (40/45)
CSF protein (g/L) 3.7 (2.1–6.9) (91/142) 1.6 (0.8–2.2)** (32/45)
CSF glucose (mmol/L) 0.9 (0.3–2.5) (95/142) 1.4 (0.4–3.2) (34/45)
CSF/blood glucose ratio 0.09 (0.02–0.3) (72/142) 0.2 (0.07–0.6) (21/45)
Positive CSF culture 93% (131/141) 100% (45/45)
Blood WBC (109 cells/L) 15.9 (10.1–24.8) (105/142) 20.3 (12.8–29.2) (29/45)
Positive blood culture 67% (94/141) 67% (30/45)
Decreased penicillin susceptibility 4% (5/139) 11% (5/45)
Death during hospitalization 27% (38/142) 2% (1/45)**
1. Neurological causes# 11% (15/142)$ 2% (1/45)
2. Systemic causes¤ 6% (9/142)$ 0% (0/45)
3. Other causes& 2% (3/142) 0% (0/45)
Combination of 1 and 2 8% (11/142) 0% (0/45)
Sequelae 52% (50/96) 17% (7/42)**
1. Hearing loss 30% (29/96) 12% (5/42)
2. Neurologic abnormalityˆ 22% (21/96) 2.5% (1/42)
Combination of 1 and 2 0% (0/96) 2.5% (1/42)
Number of days hospitalised among survivors 15 (11–22) 11 (10–14)**
* Predisposing condition was defined a previous head trauma, liquorrhoea, dura disruption etc.
§Underlying disease was defined as previous splenectomy, presence of immunodeficit, cancer, diabetes mellitus, alcoholism, or the use of 
immunosuppressive drugs.
# Includes brain herniation, cerebrovascular complications.
¤ Includes septic shock, multiple-organ dysfunction.
& Includes withdrawal of care due to incurable cancer (1 patient), gastrointestinal bleeding (+/- Bilroth II operation, 2 patients). ˆNeurologic 
abnormality was defined as presence of aphasia, ataxia and paresis at discharge.
$ 1 patient also had gastrointestinal bleeding/Billroth II operation.
**Significant difference vs. adult cases (Mann Whitney test or Fisher Exact Test, P < 0.05.BMC Infectious Diseases 2005, 5:93 http://www.biomedcentral.com/1471-2334/5/93
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Results
Identification of patients
A total of 187 cases with pneumococcal meningitis were
identified and included in the study; one case patient was
excluded, because the patient had no evidence of menin-
gitis, and the isolation of an unencapsulated pneumococ-
cal strain from the CSF was considered a laboratory
contamination (growth in 1 out of 3 cultures). A lumbal
puncture was performed on all 187 cases, except one case
patient, where the diagnosis was established postmortem
(autopsy showed purulent meninges and the growth of
pneumococci was obtained from a swap taken from the
meninges). A total of 176 out of 186 cases had a positive
CSF culture with pneumococci, whereas 10 cases had a
positive blood culture with pneumococci and biochemi-
cal evidence of meningitis including a CSF WBC count
>10 leukocytes/mL. No significant difference in routine
CSF parameters was observed between cases with or with-
out a positive CSF culture (WBC: 1799 (290–4343) vs.
4288 (85–4713); protein: 2.9 (1.5–5.8) vs. 2.6 (1.2–8.0);
glucose: 0.9 (0.3–2.6) vs. 3.5 (0.7–4.2), respectively, P >
0.05). The annual incidence rate of pneumococcal menin-
gitis in Denmark was 1.73 cases per 100.000 persons.
Clinical characteristics according to the focus (see Table 1)
A total of 57 out of 187 patients with pneumococcal men-
ingitis (30%) were identified as having an otogenic focus
(10 patients had mastoiditis), 15 out of 187 patients had
sinusitis (8%), 33 out of 187 patients had pneumonia
(18%), 4 out of 187 patients had an alternative foci (2%,
e.g. septic arthritis, subphrenic abscess), whereas no pri-
mary infection focus could be found in 78 out of 187
patients (42%). A total of 13 out of the 78 patients, where
no primary infection focus could be determined, had no
reports of an otoscopic examination. However, none of
these patients had a history of earache or suppuration
from the ear, and a CT-scan showed no ear focus in 4 of
these patients. Six patients with an otogenic focus had an
additional focus (1 patient had sinusitis and 5 patients
had pneumonia; one of these patients died), whereas 3
patients with sinusitis also had pneumonia (one of these
patients died). Other predisposing conditions than the
focus of the infection (e.g. previous head trauma, liquor-
rhoae, dura disruption) were present in 12% of cases with
the highest frequency among cases with a sinusitic focus
(27%), among cases, where no primary infection focus
was found (15%) and among cases with an otogenic focus
(11%). The retrospective review of medical records
showed that 8 out of 187 cases were initially misclassified
in the prospective registration.
There was no significant difference in clinical and demo-
graphic characteristic between the 5 focus groups (see
Table 1), except with differences in the case fatality rate
between groups (see below) and in CSF WBC (Kruskal
Wallis test, P < 0.001). CSF WBC counts were significantly
higher in otogenic cases than in sinusitic cases, than in
pneumonic cases, and than in cases with other foci, and
were significantly higher in cases, where no primary infec-
tion focus was determined as compared to sinusitic cases
and cases with other foci (see Table 1, Mann Whitney test
with Bonferonies correction, P < 0.05). The median age of
the patients was not significantly different between
groups, and the focus of infection was only in part
dependent on age groups (<16 vs. ≥ 16 years): otogenic
focus (27% (12/45) vs. 32% (45/142), respectively, P =
0.58), sinusitic focus (2% (1/45) vs. 10% (14/142),
respectively, P = 0.12), pneumonic focus (8% (3/45) vs.
20% (30/142), respectively, P = 0.03), other foci (0% (0/
45) vs. 3% (4/142), respectively, P = 0.57), and no pri-
mary infection focus (64% (29/45) vs. 35% (49/142),
respectively, P = 0.0005). Not surprisingly was headache
more frequently reported in adults than in children, and
adults had more frequently an underlying disease,
required more frequently assisted ventilation and had a
poorer outcome than children (see Table 2, P < 0.05).
On admission, fever and an altered mental status were
present in almost all cases with pneumococcal meningitis
(93% and 94%, respectively), whereas back rigidity, head-
ache, and convulsion were significantly less frequent find-
ings (57%, 41%, and 11%, respectively, P  < 0.0001).
Twenty-one case patients (11%) had a diagnostic CT-scan
before the lumbar puncture. These patients, except one
patient, who received antibiotic therapy with ceftriaxone,
were initially suspected of having another intracranial dis-
ease than meningitis (e.g. apoplexy), resulting in a delay
in the establishment of a correct diagnosis and initiation
of antibiotic therapy. Initial or empiric antibiotic therapy
included penicillin and/or a 3. generation cephalosporin
and was changed according to the susceptibility of the
pathogen to penicillin in most cases. Adjunctive therapy
with corticosteroids was given to 16% of cases with a sig-
nificantly higher treatment rate among children than
among adults (see Table 2, P < 0.001).
Case fatality rate
The case fatality rate during the first 100 days after admis-
sion varied according to the focus of infection (Log rank
test, P = 0.0005, see Figure 1). Patients with an otogenic
focus had a significant lower case fatality rate than non-
otogenic cases (within 14 days: 7% vs. 21%, Log-rank test:
P = 0.03, within 31 days: 7% vs. 22%, P = 0.02, and within
100 days: 7% vs. 29%, P = 0.002). Adult patients had a sig-
nificantly higher case fatality rate than children (see Figure
2, and Table 2, P = 0.0001). The case fatality rate according
to serotype distribution is shown in Figure 3, and a trend
was seen for different case fatality rates among serotypes.
The most frequent serotypes according to the focus were
as follows: Otogenic focus: serotype 8(6), 3(4), 6B(4),BMC Infectious Diseases 2005, 5:93 http://www.biomedcentral.com/1471-2334/5/93
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19F(4), 12F(3), and 7F(3). Sinusitic focus: serotype 7F(3),
6B(2), 10A(2), and 35F(2). Pneumonic focus: serotype
4(5), 14(4), 7F(3), 8(3), and 9V(3). Other kind of focus:
serotype 6A(1), 12F(1), 14(1), and 22F(1). No primary
infection focus: serotype 7F(8), 6B(7), 12F(6), 23F(6),
6A(5), 9V(5), and 18C(5). Ten out of 184 isolates (5%)
had reduced susceptibility for penicillin (serotype 5 (2),
6B (1), 9N (1), 9V (1), 14 (1), 15B (2), and 19F (2); no
data available for 3 isolates). No significant differences
between case fatality rate penicillin susceptibility were
observed (P > 0.05).
Two out of every 3 deaths due to pneumococcal meningi-
tis occurred within the first week after admission, and all
patients died during hospitalisation, except 2 patients; 1
with severe brain damage (vegetative state) and 1 one
with severe cardiovascular complications, who died 57
and 61 days after admission, respectively. These two
patients were transferred to a nursing home for a short
period before time of death/readmission and death at the
hospital. The causes of death during hospitalisation was
as follows: 41% died due to neurological causes (e.g.
brain herniation, cerebrovascular complications), 23%
died due to systemic causes (e.g. septic shock, multiple-
organ dysfunction), 8% died due to other causes (e.g. gas-
trointestinal bleeding, incurable cancer) and 28% died
due to a combination of systemic and neurological com-
plications. Gastrointestinal bleeding was observed in a
total of 5 patients dying from pneumococcal meningitis
(2 patients had a Billroth II operation); none of these were
treated with steroids. The median time to death due to
neurological -, systemic -, other complications or the com-
bination of neurological and systemic complications was
2 days (3–30), 7 days (4–9), 47 days (11–61), and 6 days
(3–10), respectively (Kruskal Wallis test P = 0.07).
Prognostic factors
Patients with advanced age, with an underlying disease,
without an otogenic focus, with a lung focus and with
convulsions, as well as patients, who had a CT-scan before
lumbar puncture, and who required assisted ventilation
were at increased risk for fatal outcome (within 100 days)
in univariate logistic regression analysis (P < 0.05, see
Table 3). Also, an association was found between case
fatality rate and various alterations in CSF parameters
(WBC< 500 cells/µL, high protein levels, glucose levels <1
mmol/L, low CSF/blood glucose ratios), P < 0.05. In the
multivariate analysis (not including assisted ventilation
therapy and variables with less than 80% available val-
ues), prognostic factors for fatal outcome due to pneumo-
coccal meningitis were convulsions, whereas presence of
an otogenic focus was independently associated with a
better survival (see Table 3, P < 0.05). Stepwise inclusion
of other possible prognostic factors did not weaken the
association between a better survival and presence of an
otogenic focus (data not shown) Independent prognostic
factors for fatal outcome during hospitalisation were sim-
ilar to the 100 days calculation (data not shown), and
independent risk factors for dying within 31 days after
admission were having a CT-scan preceding lumbar punc-
ture (OR: 4.13 (1.36–12.6), P = 0.01), and absence of an
otogenic focus (OR: 3.61 (1.09–12.0), P = 0.036). Not
surprisingly, assisted ventilation was independently asso-
ciated with fatal outcome (OR: 9.45 (3.18–28.1), P <
0.001) and when included in the multivariate analysis,
convulsion and presence of an otogenic focus were still
significant associated with a higher and lower case fatality
rate at 100 days, respectively (OR: 3.15 (1.11–8.94), P =
0.03 and OR: 6.68 (1.71–26.1), P = 0.006, respectively).
Sequelae among survivors of pneumococcal meningitis
Sequelae were present in 41% (57/138) of survivors with
various degree of hearing loss in ~25% of survivors, and
motor sequelae such as ataxia and paresis were present in
~16% of survivors. Among survivors, adult patients had
significantly more frequent sequelae than children (see
Table 2, P < 0.001), and the median age was significantly
higher among patients with – than without sequelae (57
years (50–71) vs. 29 years (1–61), respectively, P < 0.001).
Sequelae among survivors were significantly more fre-
quent in patients, who required assisted ventilation (65%
(37/57) vs. 23% (15/65), P < 0.001), in patients, who
were not treated with corticosteroids 47% (47/100) vs.
13% (3/23), P = 0.004), and patients with sequelae had
significantly higher CSF protein levels (3,0 (2.1–4.6) vs.
1.6 (1.0–5.5), P = 0.016 and lower CSF glucose levels 0.7
(0.3–1.6) vs. 1.9 (0.6–3.4), P = 0.002, respectively) than
in patients without sequelae.
Kaplan Meier Survival curve of 187 patients with S. pneumo- niae meningitis in Denmark 1999–2000 according to the  focus of the infection Figure 1
Kaplan Meier Survival curve of 187 patients with S. 
pneumoniae meningitis in Denmark 1999–2000 
according to the focus of the infection. Otogenic focus 
vs. pneumonic focus, sinusitic focus, other foci, and no pri-
mary infection focus: Log rank test: P = 0.0002, 0.008, 
<0.0001, and 0.03, respectively. Other foci vs. no primary 
infection focus: P = 0.01.BMC Infectious Diseases 2005, 5:93 http://www.biomedcentral.com/1471-2334/5/93
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Discussion
The present nationwide study of 187 consecutive cases
with pneumococcal meningitis in Denmark over a 2-year
period (1999–2000) shows that the overall case fatality
rate was 21% with a 10-fold higher mortality rate among
adults than among children, which is comparable with
recent reports from other industrialised countries
[5,6,9,19-21]. The case fatality rate according to age
groups seems to resemble previous findings obtained
from patients with pneumococcal meningitis admitted to
a tertiary Danish hospital during the period 1966–1976
[4] indicating that the epidemiology as well as the mortal-
ity of pneumococcal meningitis has not changed signifi-
cantly over a 30–40 years period. Also, the present study
confirms that predisposing conditions (e.g. dura leakage
and associated foci) are found in 2 out of every 3 patients
with pneumococcal meningitis [3-5]. An otogenic focus
was the most frequent focus (30%) followed by a pneu-
monic focus (18%), a sinusitic focus (8%), whereas no
primary infection focus was found in 42% of cases with
pneumococcal meningitis. A high proportion of cases
were children, when no primary infection focus was
detected, despite of thoroughly examination for other
infection foci, which could indicate that nasopharyngeal
colonisation with pneumococci may be a risk factor for
developing pneumococcal meningitis particular in chil-
dren.
The case fatality rate varied according to the focus of infec-
tion with a significantly lower case fatality rate among
otogenic cases (7%) as compared to non-otogenic cases of
pneumococcal meningitis (27%). Others have reported
Age distribution and mortality of 187 patients with S. pneumoniae meningitis in Denmark 1999–2000 Figure 2
Age distribution and mortality of 187 patients with S. pneumoniae meningitis in Denmark 1999–2000.BMC Infectious Diseases 2005, 5:93 http://www.biomedcentral.com/1471-2334/5/93
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similar trends for a better outcome of otogenic pneumo-
coccal meningitis [4]. A lung focus was associated with a
higher case fatality rate (26%) as reported by other studies
[4,5,14]. Underlying diseases could be a likely explana-
tion, why patients with a lung focus have a poorer out-
come than patient with an otogenic focus (36% vs. 14%,
respectively, with Bonferonis correction: P = 0.19). How-
ever, an otogenic focus remained an independent prog-
nostic factor after inclusion of other prognostic factors in
the multivariate analysis.
Whilst several studies have investigated prognostic factors
in pneumococcal meningitis, most of these studies have
been smaller in size than the present study or have not
applied multivariate statistics in their risk factor analysis
[3-5,9-17]. The identification of other independent risk
factors for fatal outcome than the focus of the infection in
the multivariate analysis (convulsions) and in the univar-
iate analysis (advanced age, having an underlying disease,
presence of a lung focus, having a CT-scan prior to lumbar
puncture, need for assisted ventilation, alterations in var-
ious CSF cytochemical parameters (e.g. low WBC counts,
high protein and glucose levels)) confirms in part findings
inconsistently obtained in previous studies [3-6,9-17].
Almost all patients with pneumococcal meningitis had
fever and an altered mental status on admission (~94%),
whereas nucal rigidity, the "classic sign" of meningitis,
was present in 57% of patients. Consequently, some
patients were admitted to the hospital suspected of having
Serotype distribution and mortality of 187 patients with S. pneumoniae meningitis in Denmark 1999–2000 Figure 3
Serotype distribution and mortality of 187 patients with S. pneumoniae meningitis in Denmark 1999–2000. *10 
isolates were not capsular serotyped.BMC Infectious Diseases 2005, 5:93 http://www.biomedcentral.com/1471-2334/5/93
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other kind of intracranial disease (e.g. apoplexy) than
meningitis, and a diagnostic CT-scan was performed
before the lumbar puncture with a subsequent delay in
establishing the meningitis diagnosis and initiation of
antibiotic therapy. Others have previously shown that a
delay in the initiation of antibiotic therapy worsen the
clinical outcome of community-acquired bacterial menin-
gitis [22]. Thus, the results support international recom-
mendation that patients presenting with fever and altered
mental status should promptly have a diagnostic lumbar
puncture or be given empirical antibiotic therapy and cor-
ticosteroids, and be sampled for blood culture before the
CT-scan [23].
Less than 10% of patients were infected with pneumococ-
cal strains with reduced susceptibility to penicillin, which
was not related to a poorer outcome. Similar results have
previously been found in countries with low or high levels
of penicillin resistance [6,12,24]. Previously, we have
shown that serotype-related differences (between serotype
1, 3, and 9 V) in mortality of pneumococcal meningitis
exists [25]. The results from the present study may indi-
cate that a relationship to mortality may exist for other
serotypes, however, this has to be addressed in a larger
patient population. The serotype coverage rate by the 7-,
9-, and 11-valent pneumococcal conjugate vaccine were
67%, 72%, and 86%, respectively, among children less
than 2 years of age, and by the 23-valent vaccine it was
92% among adults, which is in accordance with previous
published results obtained in Denmark during the period
1995–1999 [26]. No reliable data could be extracted from
the present study on the vaccination status of the individ-
ual patients against pneumococcal infection due to
incomplete data registration, but a more frequent use of
pneumococcal vaccination may likely reduce the inci-
dence of pneumococcal meningitis in Denmark, since
Table 3: Prognostic clinical parameters for fatal outcome# due to S. pneumoniae meningitis
Univariat analysis Multivariate
% or median (25/75 percentiles) 
and (No/total)
Non-survivors N = 41 Survivors N = 146 OR¤ P-value OR¤ P-value
Sex (female) 51% (21/41) 48% (70/146) 1.14 (0.57–2.28) 0.71
Age (in years) 67 (56–74) 50 (1–67) 1.036 (1.02–1.06) <0.001 1.03 (1.00–1.07) 0.05
Age ≤ 16 years 2% (1/41) 30% (44/146) 0.06 (0.008–0.44) 0.006 0.36 (0.02–7.13) 0.50
Predisposing condition* 10% (4/40) 13% (19/145) 0.74 (0.24–2.30) 0.60
Underlying disease§ 30% (12/40) 15% (21/145) 2.53 (1.12–5.74) 0.03 1.72 (0.58–5.08) 0.33
Admission during the first half of 
the year
83% (34/41) 68% (99/146) 2.30 (0.95–5.58) 0.06 1.27 (0.41–3.97) 0.68
Fever 95% (35/37) 97% (125/129) 0.56 (0.10–3.19) 0.61
History of headache 62% (13/21) 38% (35/95) 2.79 (1.05–7.38) 0.04
Back rigidity 55% (16/29) 57% (70/122) 0.91 (0.40–2.07) 0.84
Decreased consciousness 98% (40/41) 93% (125/135) 3.20 (0.40–25.8) 0.46
Convulsion 53% (19/36) 25% (35/139) 2.32 (1.07–5.04) 0.03 4.53 (1.74–11.8) 0.002
Mechanical ventilation& 90% (35/39) 48% (62/129) 9.45 (3.18–28.1) <0.001
CT-scan preceding lumbar 
puncture
22% (9/41) 8% (12/146) 3.14 (1.22–8.01) 0.02 2.62 (0.82–8.41) 0.11
Steroid therapy 9% (3/32) 18% (23/131) 0.49 (0.14–1.73) 0.27
Bacteraemia 78% (31/40) 64% (93/146) 1.96 (0.87–4.43) 0.11 2.02 (0.70–5.84) 0.19
Otogenic focus 10% (4/41) 36% (53/146) 0.19 (0.06–0.56) 0.003 0.16 (0.05–0.57) 0.005
Lung focus 39% (16/41) 17% (25/146) 3.10 (1.45–6.63) 0.004 1.46 (0.53–3.97) 0.46
CSF WBC (109 cells/L) 0.32 (0.07–3.1) (33/41) 11 (0.7–4.7) (116/146) 0.88 (0.77–1.01) 0.06
500 cells/µL 55% (18/33) 22% (26/116) 4.15 (1.84–9.36) 0.001
CSF protein (g/L) 4.7 (2.7–8.9) (27/41) 2.4 (1.3–4.8) (96/146) 1.19 (1.07–1.33) 0.001
CSF glucose (mmol/L)  0.4 (0.1–1.6) (29/41)  1.0 (0.4–3.1) (100/146)  0.83 (0.63–1.08)  0.17 
<1 mmol/L 76% (22/29) 52% (52/100) 3.41 (1.33–8.69) 0.01
CSF/blood glucose ratio 0.05 (0.01–0.11) (21/41) 0.18 (0.06–0.5) (72/146) 0.01 (0.00–0.36) 0.01
Blood WBC (109 cells/L) 14.8 (9.5–24.1) (28/41) 17.7 (10.8–26.8) (106/146) 0.98 (0.94–1.02) 0.34
# Within 100 days after admission.
¤ OR was calculated per additional units for continuous data.
* Predisposing condition was defined a previous head trauma, liquorrhoea, dura disruption etc.
§Underlying disease was defined as previous splenectomy, presence of immunodeficit, cancer, diabetes mellitus, alcoholism, or the use of 
immunosuppressive drugs.
& If need for assisted ventilation was included in the multivariate analysis convulsions, absence of otogenic focus, and need for assisted ventilation 
were of significant importance for fatal outcome (p < 0.05, data not shown).BMC Infectious Diseases 2005, 5:93 http://www.biomedcentral.com/1471-2334/5/93
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vaccination of children and adults has reduced the risk for
developing invasive pneumococcal disease in other coun-
tries [27,28].
The causes of death in patients with pneumococcal men-
ingitis are multifactoral and involve both neurological
and systemic complications [5]. Three patients died due to
other causes (two patients due to gastrointestinal bleeding
and one patient, because active therapy was stopped due
of incurable cancer). Interestingly, no significant differ-
ences were observed in the causes of death between the
five different groups of infection foci. Two out of every
three patients died within the first week after admission,
however, death directly related to pneumococcal menin-
gitis still occurred up to 96 days after admission. Others
have previously found that a mortality at 14 days as the
endpoint is optimal to use when studying community-
acquired bacterial meningitis [18]. Our results here and in
a previous study suggest a longer study period, when stud-
ying case fatality in pneumococcal meningitis [25].
The frequency of sequelae due to pneumococcal meningi-
tis was 41% with hearing loss in 26% of survivors and
neurological sequelae in 16% of survivors, confirming
previous results [1,4,6,10]. Sequelae occurred more fre-
quently in adults than in children, most likely because
pneumococcal meningitis is a less severe disease in chil-
dren than in adults, as shown in the present study, or due
to a higher susceptibility for the host to develop sequelae
with increasing age. On the other hand, sequelae were
detected more frequently in otogenic cases than in non-
otogenic cases, despite a lower mortality rate in otogenic
cases. However, there is one major bias in the evaluation
of sequelae among meningitis patients, in particular with
the evaluation of hearing loss, since it is not possible to
compare the outcome with baseline parameters obtained
before the onset of meningitis, which may have a signifi-
cant impact on the interpretation of the results.
Whereas a beneficial effect of adjunctive therapy with cor-
ticosteroids on mortality did not reach statistical signifi-
cance, surviving patients, who were treated with
corticosteroids, had a significantly lower risk of develop-
ing sequelae than patients, who were not treated with cor-
ticosteroids. International guidelines and results from
well-designed randomised trials have recommended the
use of corticosteroids as adjunctive therapy of pneumo-
coccal meningitis, when administered before or together
with the first dose of antibiotics [1,23,29], but informa-
tion's on the exact timing of corticosteroid administration
could not be extracted from the medical records in the
present study. Moreover, the majority of patients, who
received corticosteroids in the present study, were chil-
dren, because the study period was before the publication
of the results of the European Dexamethasone in Adult-
hood Bacterial Meningitis Study in 2002 [1] and before
the recommendation in Denmark to use corticosteroids as
adjunctive therapy in adult bacterial meningitis [30].
Indeed, this affected the results significantly, and no ben-
eficial effect of corticosteroid therapy was observed, when
sub-analysis among children or adult cases were per-
formed (P > 0.05, data not shown). However, the case
fatality rate of pneumococcal meningitis will be expected
to be lower in future studies performed after the imple-
mentation of corticosteroids as adjunctive therapy to all
cases of bacterial meningitis.
Although new knowledge in the pathogenesis of pneumo-
coccal meningitis has been obtained experimentally [31],
the exact infection route into the CNS is not fully deter-
mined. Pneumococci may spread directly from an adja-
cent focus or via the haematogenously route into the CNS.
In the present study, bacteraemia was present in 2 out of
every 3 cases, and no significant difference in frequency of
bacteraemia was observed between the 5 different groups
of infection foci, indicating that pneumococci predomi-
nantly may spread haematougenously. However, bacter-
aemia also occurs secondary to meningitis, as shown in
animal models after intracisternal inoculation [25].
Therefore, clinical studies with quantitative CSF and
blood cultures from cases with different foci of the infec-
tion are required to provide further insight in the patho-
genesis of pneumococcal meningitis.
The present study has limitations because not all data was
collected prospectively, and several variables were una-
vailable from a number of cases leading to a decreased sta-
tistical power of the multivariate analysis. Also, we could
not detect an association between degree of consciousness
and case fatality rate, most likely because Glasgow Coma
Scale tests were not performed on the patients, and
thereby missing one of the most important predictors of a
poor clinical outcome [5,6]. The results of the present
study should be confirmed in future studies (i.e. in suba-
nalysis of pneumococcal cases from prospective studies
with less missing values [6]).
Conclusion
Our results emphasize the prognostic importance of early
recognition of a primary infection focus in pneumococcal
meningitis. Meningitis should also be considered in
patients presenting without nucal rigidity but with fever
and altered mental status. Finally, a diagnostic lumbar
puncture or start of antibiotic therapy and blood culture
sampling should not be delayed by a CT-scan.
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